Application of pharmaceutical composition containing hydroxyurea

A technology of hydroxyurea and composition, which is applied in the application field of pharmaceutical composition, and can solve problems such as reduction of atherosclerotic plaque area, limited therapeutic effect, no synergistic effect, and superimposed effect of drug effects

Active Publication Date: 2019-05-28
JILIN UNIV +1
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the complexity of the etiology of atherosclerosis, the current clinical treatment options are still very limited
When the drug effect of single administration reaches a certain level, it is very difficult to combine other drugs to enhance the drug effect, such as the combination of oral aspirin and clopidogrel bisulfate, or oral administration of atorv

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pharmaceutical composition containing hydroxyurea
  • Application of pharmaceutical composition containing hydroxyurea
  • Application of pharmaceutical composition containing hydroxyurea

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1. The combined treatment of hydroxyurea and conventional drugs (statin and anticoagulant drugs) in clinical patients significantly improved the degree of atherosclerotic stenosis

[0045] Coronary angiography is an important method for clinically examining the degree of vascular stenosis. A patient with acute coronary syndrome previously diagnosed with severe atherosclerotic stenosis in the anterior descending artery confirmed by coronary angiography and essential thrombocythemia was treated with aspirin, clopidogrel bisulfate and statin At the same time, hydroxyurea (100mg×1 / day) was taken. After treatment, coronary angiography showed that the vascular atherosclerotic lesions improved unexpectedly, the degree of the original stenosis disappeared, the vessel wall became smooth, and basically returned to normal state. See figure 1 , figure 1 Coronary angiography images before and after treatment with hydroxyurea and other drugs for patients undergoing coronar...

Embodiment 2

[0047] Example 2. The pharmaceutical composition containing hydroxyurea in the atherosclerosis model ApoE induced by high-fat diet - / - Therapeutic Effects in Mice

[0048] Comparison of oil red O pathological sections of aorta, HE pathological sections of aorta, and full-length oil red O staining images of aorta is an important index for evaluating the therapeutic effect of atherosclerosis. Blood glucose content, triglyceride content, total cholesterol content, and low-density lipoprotein cholesterol content are important indicators for evaluating risk factors for atherosclerosis. The content of blood alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatinine is one of the important indicators for evaluating the liver and kidney function of animals with atherosclerosis.

[0049] 1. Experimental animals, instruments and pharmaceutical reagents

[0050] C57 mice (8 weeks old) and ApoE - / - Mice (8 weeks old) were purchased from Beijing Weitong Lihua Anima...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides an application of a pharmaceutical composition containing hydroxyurea, and hydroxyurea or pharmaceutically acceptable salts thereof are used for preparation of medicinesfor preventing and/or treating atherosclerosis. The results of an experiment show that after oral administration of combination of hydroxyurea, aspirin and clopidogrel hydrogen sulfate, aortic intimafat and porridge-like lesion regions are significantly reduced, the drug effect on atherosclerosis is obvious (plaque inhibition degree 85%), the concentration of blood glucose, triglyceride, total cholesterol, low-density lipoprotein cholesterol is decreased, and glycolipid metabolism disorder is significantly improved; after oral administration of combination of hydroxyurea, aspirin, clopidogrel hydrogen sulfate and atorvastatin calcium, aortic intima fat and porridge-like lesion regions are significantly reduced, and atherosclerosis is essentially cured (plaque inhibition degree 91%). Thecombination of drugs at this dose has an outstanding therapeutic effect in the prevention and/or treatment of atherosclerosis.

Description

[0001] This application claims the priority of the Chinese patent application submitted to the China Patent Office on January 23, 2019, with the application number 201910063116.2, and the title of the invention is "A Hydroxyurea and Its Salts and Applications of Pharmaceutical Compositions Including It" , the entire contents of which are incorporated in this application by reference. technical field [0002] The invention belongs to the technical field of medicine, and in particular relates to the application of a pharmaceutical composition comprising hydroxyurea or a salt thereof. Background technique [0003] With the development of the economy and the improvement of people's living standards, cardiovascular disease has become the number one killer of human beings, and as the common pathological basis of cardiovascular and cerebrovascular diseases such as coronary heart disease, cerebral infarction, and peripheral vascular disease, atherosclerosis is seriously harmful It a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/17A61K31/40A61K31/4365A61K31/616A61P9/10
CPCA61K31/17A61K31/40A61K31/4365A61K31/616A61P9/10
Inventor 佟倩王琰蒋建东张显峰马殊荣于金波丛林
Owner JILIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap